

Special Issue

Nanoparticle-Mediated Diagnosis and Treatment of Human Disease

Message from the Guest Editor

Nanotechnology has opened up unique opportunities for diagnosis and treatment options due to particularities such as size, functionalization potential, as well as multimodal and synchronous mechanisms of action on living cells. This Special Edition is aiming to gather novel insights into the most recent directions toward nanotechnology-mediated diagnosis and treatment of human disease. Studies on nanopharmaceutical solutions designed for widely studied pathologies such as cancer, antimicrobial applications, and osteoregenerative applications are welcomed, together with more recent orientations, such as hematology, tissue regeneration, etc. Photothermal, nanotargeting, direct toxicity or other mechanistic approaches will equally find a place in this issue. Evaluations of pharmacological biodistribution and bioavailability, pharmacokinetics, and toxicity for newly designed nanostructures, as part of human disease prevention and diagnosis are also welcomed. High-quality theoretical reviews opening the path to novel pharmaceutical applications of nanoparticles in the diagnosis and treatment of human disorders will also be an integral part of this issue.

Guest Editor

Dr. Teodora Mocan

Physiology Department, Faculty of Medicine, "Iuliu Hațieganu"
University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania

Deadline for manuscript submissions

closed (20 April 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/111904

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).